Year archive

CSPC Pharmaceutical Group Limited — 2025 filings

All 144 regulatory filings released by CSPC Pharmaceutical Group Limited (1093) in 2025, sourced directly from the official regulator.

144 Filings

2025 Period

2025 filings (144)

Filing	Released	Lang
VOLUNTARY ANNOUNCEMENT - POTENT ALDOSTERONE SYNTHASE INHIBITOR (SYH2072 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-12-29	English
VOLUNTARY ANNOUNCEMENT - PRUSOGLIPTIN, DAPAGLIFLOZIN AND METFORMIN EXTENDED-RELEASE TABLETS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-12-29	English
VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE INJECTION (SYH2069 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-12-29	English
VOLUNTARY ANNOUNCEMENT - DARATUMUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-12-23	English
VOLUNTARY ANNOUNCEMENT - SYH2085 TABLETS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-12-19	English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION Board/Management Information	2025-12-19	English
(1) APPOINTMENT OF EXECUTIVE DIRECTORS; (2) CHANGE OF VICE-CHAIRMAN, CHIEF EXECUTIVE OFFICER AND AUTHORISED REPRESENTATIVE; AND (3) APPOINTMENT OF CHIEF OPERATING OFFICER Board/Management Information	2025-12-19	English
VOLUNTARY ANNOUNCEMENT - TOPLINE RESULTS OBTAINED FROM PHASE III CLINICAL TRIAL OF SECUKINUMAB INJECTION Regulatory Filings	2025-12-18	English
VOLUNTARY ANNOUNCEMENT - NEW INDICATION FOR DUOENYI (IRINOTECAN HYDROCHLORIDE LIPOSOME INJECTION) OBTAINS MARKETING APPROVAL Regulatory Filings	2025-12-12	English
FURTHER ANNOUNCEMENT - UPDATE ON DISCLOSEABLE TRANSACTION IN RELATION TO THE PROPOSED H SHARE LISTING OF CSPC INNOVATION M&A Activity	2025-12-11	English
VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-ACTRIIA/IIB MONOCLONAL ANTIBODY (JMT206) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-12-10	English
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS SECOND MARKETING AUTHORISATION APPLICATION FOR SEMAGLUTIDE INJECTION Regulatory Filings	2025-12-08	English
VOLUNTARY ANNOUNCEMENT - GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE INJECTION (SYH2069 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-12-05	English
VOLUNTARY ANNOUNCEMENT - A SELECTIVE 5-HT2A RECEPTOR AGONIST (SYH2056 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-12-03	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2025 Share Issue/Capital Change	2025-12-01	English
VOLUNTARY ANNOUNCEMENT - RECOMBINANT FULLY HUMAN ANTI-ACTRIIA/IIB MONOCLONAL ANTIBODY (JMT206) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-11-26	English
VOLUNTARY ANNOUNCEMENT - A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG (SYH2061 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-11-24	English
VOLUNTARY ANNOUNCEMENT - A SELECTIVE 5-HT2A RECEPTOR AGONIST (SYH2056 TABLETS) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-11-21	English
APPOINTMENT OF AN EXECUTIVE DIRECTOR Board/Management Information	2025-11-21	English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION Governance Information	2025-11-21	English
QUARTERLY RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025 Interim / Quarterly Report 9M 2025	2025-11-20	English
VOLUNTARY ANNOUNCEMENT - MARKETING AUTHORISATION APPLICATION FOR PERTUZUMAB INJECTION ACCEPTED BY THE NMPA Regulatory Filings	2025-11-12	English
DATE OF BOARD MEETING Report Publication Announcement	2025-11-10	English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION Governance Information	2025-11-04	English
RESIGNATION OF EXECUTIVE DIRECTOR AND CHANGE OF AUTHORISED REPRESENTATIVE Board/Management Information	2025-11-04	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2025 Regulatory Filings	2025-11-03	English
ANNOUNCEMENT MADE PURSUANT TO RULES 13.51B(2) AND 13.51(2) OF THE LISTING RULES Director's Dealing	2025-11-02	English
UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025 Interim / Quarterly Report 9M 2025	2025-10-27	English
VOLUNTARY ANNOUNCEMENT - SYH2061 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-10-24	English
VOLUNTARY ANNOUNCEMENT - JSKN003 GRANTED ANOTHER BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE ADVANCED COLORECTAL CANCER Regulatory Filings	2025-10-20	English
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY Transaction in Own Shares	2025-10-17	English
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY Transaction in Own Shares	2025-10-16	English
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY Transaction in Own Shares	2025-10-15	English
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY Transaction in Own Shares	2025-10-14	English
VOLUNTARY ANNOUNCEMENT - ON-MARKET PURCHASE OF SHARES PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY Transaction in Own Shares	2025-10-13	English
VOLUNTARY ANNOUNCEMENT - TACROLIMUS EXTENDED-RELEASE CAPSULES OBTAIN DRUG REGISTRATION APPROVAL Regulatory Filings	2025-10-13	English
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR EFMEDAGLUTIDE ALFA INJECTION ACCEPTED BY THE NMPA Regulatory Filings	2025-10-13	English
VOLUNTARY ANNOUNCEMENT - SYH2070 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-10-09	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2025 Share Issue/Capital Change	2025-10-02	English
DISCLOSEABLE TRANSACTION - DEEMED DISPOSAL OF EQUITY INTEREST IN CSPC INNOVATION ARISING FROM THE PROPOSED LISTING OF THE H SHARES OF CSPC INNOVATION Share Issue/Capital Change	2025-09-30	English
VOLUNTARY ANNOUNCEMENT - SYH2070 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-09-30	English
VOLUNTARY ANNOUNCEMENT - LECANEMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-09-25	English
VOLUNTARY ANNOUNCEMENT - GRANT OF SHARE AWARDS PURSUANT TO THE SHARE AWARD SCHEME OF THE COMPANY Share Issue/Capital Change	2025-09-19	English
NOTIFICATION LETTER TO NON-REGISTERED HOLDER AND REQUEST FORM Report Publication Announcement	2025-09-18	English
NOTIFICATION LETTER TO SHAREHOLDER AND CHANGE REQUEST FORM Report Publication Announcement	2025-09-18	English
2025 INTERIM REPORT Interim / Quarterly Report H1 2025	2025-09-18	English
LETTER TO NEW REGISTERED SHAREHOLDERS AND REPLY FORM Regulatory Filings	2025-09-18	English
VOLUNTARY ANNOUNCEMENT - ALMB-0166 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR THE TREATMENT OF PARKINSON'S DISEASE Regulatory Filings	2025-09-15	English
VOLUNTARY ANNOUNCEMENT - SYH2066 TABLETS OBTAIN CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-09-12	English
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR KN026 (ANBENITAMAB INJECTION) ACCEPTED BY THE NMPA Regulatory Filings	2025-09-11	English
NEXT DAY DISCLOSURE RETURNS Transaction in Own Shares	2025-09-02	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2025 Regulatory Filings	2025-09-01	English
VOLUNTARY ANNOUNCEMENT - SYS6036 INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-08-22	English
2025 INTERIM DIVIDEND Notice of Dividend Amount	2025-08-22	English
2025 INTERIM RESULTS Interim / Quarterly Report H1 2025	2025-08-22	English
VOLUNTARY ANNOUNCEMENT - DUPILUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-08-19	English
UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE SIX MONTHS ENDED 30 JUNE 2025 Interim / Quarterly Report H2 2025	2025-08-15	English
DATE OF BOARD MEETING Regulatory Filings	2025-08-12	English
VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTANCE OF APPLICATION FOR MARKETING APPROVAL OF SEMAGLUTIDE INJECTION Regulatory Filings	2025-08-05	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2025 Regulatory Filings	2025-08-04	English
VOLUNTARY ANNOUNCEMENT - ENTERING INTO EXCLUSIVE LICENSE AGREEMENT FOR SYH2086 WITH MADRIGAL Regulatory Filings	2025-07-30	English
NEXT DAY DISCLOSURE RETURNS Share Issue/Capital Change	2025-07-21	English
VOLUNTARY ANNOUNCEMENT - MESALAZINE ENTERIC-COATED TABLETS OBTAIN DRUG REGISTRATION APPROVAL Regulatory Filings	2025-07-04	English
VOLUNTARY ANNOUNCEMENT - HIGH-CONCENTRATION HYDROXOCOBALAMIN HYDROCHLORIDE INJECTION OBTAINS CLINICAL TRIAL APPROVAL IN CHINA FOR THE TREATMENT OF METHYLMALONIC ACIDEMIA (MMA) Regulatory Filings	2025-07-03	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2025 Share Issue/Capital Change	2025-07-03	English
NOMINATION COMMITTEE - TERMS OF REFERENCE Governance Information	2025-06-27	English
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION Board/Management Information	2025-06-27	English
CHANGE IN COMPOSITION OF NOMINATION COMMITTEE Board/Management Information	2025-06-27	English
CONNECTED TRANSACTIONS - LEASE AGREEMENTS Regulatory Filings	2025-06-24	English
VOLUNTARY ANNOUNCEMENT - MELOXICAM INJECTION (III) OBTAINS DRUG REGISTRATION APPROVAL Regulatory Filings	2025-06-23	English
NEXT DAY DISCLOSURE RETURNS Share Issue/Capital Change	2025-06-20	English
VOLUNTARY ANNOUNCEMENT - ENTERING INTO STRATEGIC RESEARCH COLLABORATION AGREEMENT WITH ASTRAZENECA Regulatory Filings	2025-06-13	English
VOLUNTARY ANNOUNCEMENT - SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-06-10	English
VOLUNTARY ANNOUNCEMENT - COBAMAMIDE CAPSULES OBTAIN DRUG REGISTRATION APPROVAL Regulatory Filings	2025-06-05	English
VOLUNTARY ANNOUNCEMENT - JMT101 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF COLORECTAL CANCER Regulatory Filings	2025-06-02	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2025 Regulatory Filings	2025-06-02	English
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 30 MAY 2025 Declaration of Voting Results & Voting Rights Announcements	2025-05-30	English
VOLUNTARY ANNOUNCEMENT - POTENTIAL LICENSE AND COLLABORATION Regulatory Filings	2025-05-30	English
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2025 Interim / Quarterly Report Q1 2025	2025-05-29	English
VOLUNTARY ANNOUNCEMENT - CPO301 GRANTED THE THIRD FAST TRACK DESIGNATION BY U.S. FDA FOR THE TREATMENT OF ADULT PATIENTS WITH NSCLC Regulatory Filings	2025-05-19	English
VOLUNTARY ANNOUNCEMENT - JMT106 (BISPECIFIC FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-05-19	English
DATE OF BOARD MEETING Report Publication Announcement	2025-05-19	English
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH CIPLA USA, INC. FOR IRINOTECAN LIPOSOME INJECTION Regulatory Filings	2025-05-15	English
VOLUNTARY ANNOUNCEMENT - VONOPRAZAN FUMARATE TABLETS OBTAINS DRUG REGISTRATION APPROVAL Regulatory Filings	2025-05-12	English
PROXY FORM (REVISED) FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON 30 MAY 2025 AT 10:00 A.M. (AND AT ANY ADJOURNMENT THEREOF) Proxy Solicitation & Information Statement	2025-05-09	English
VOLUNTARY ANNOUNCEMENT - SYH2046 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-05-09	English
NEXT DAY DISCLOSURE RETURNS Transaction in Own Shares	2025-05-09	English
VOLUNTARY ANNOUNCEMENT - JMT202 (RECOMBINANT FULLY HUMAN ANTI-BETA KLOTHO MONOCLONAL ANTIBODY DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-05-02	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2025 Regulatory Filings	2025-05-02	English
VOLUNTARY ANNOUNCEMENT - PIVOTAL PHASE II/III CLINICAL STUDY OF KN026 MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AT INTERIM ANALYSIS Regulatory Filings	2025-04-30	English
NOTIFICATION LETTER TO NON-REGISTERED HOLDER AND REQUEST FORM Report Publication Announcement	2025-04-28	English
NOTIFICATION LETTER TO SHAREHOLDER AND CHANGE REQUEST FORM Report Publication Announcement	2025-04-28	English
LETTER TO NEW REGISTERED SHAREHOLDERS AND REPLY FORM Regulatory Filings	2025-04-28	English
PROXY FORM FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON 30 MAY 2025 AT 10:00 A.M. (AND AT ANY ADJOURNMENT THEREOF) Proxy Solicitation & Information Statement	2025-04-28	English
NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-04-28	English
PROPOSALS FOR GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE SHARES, MANDATE TO GRANT OPTIONS AND RE-ELECTION OF RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-04-28	English
2024 Environmental, Social and Governance Report Environmental & Social Information	2025-04-28	English
2024 ANNUAL REPORT Annual Report FY 2024	2025-04-28	English
VOLUNTARY ANNOUNCEMENT - SYH2068 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL Regulatory Filings	2025-04-25	English
UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2025 Regulatory Filings Q1 2025	2025-04-23	English
VOLUNTARY ANNOUNCEMENT - PRUSOGLIPTIN AND METFORMIN EXTENDED-RELEASE TABLETS OBTAINS CLINICAL TRIAL APPROVAL Regulatory Filings	2025-04-22	English
VOLUNTARY ANNOUNCEMENT - JMT203 (ANTI-GFRAL MONOCLONAL ANTIBODY) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-04-22	English
VOLUNTARY ANNOUNCEMENT - OSELTAMIVIR PHOSPHATE FOR SUSPENSION OBTAINS DRUG REGISTRATION APPROVAL Regulatory Filings	2025-04-15	English
VOLUNTARY ANNOUNCEMENT - SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-04-14	English
VOLUNTARY ANNOUNCEMENT - SYH2046 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-04-11	English
NEXT DAY DISCLOSURE RETURNS Transaction in Own Shares	2025-04-09	English
NEXT DAY DISCLOSURE RETURNS Transaction in Own Shares	2025-04-08	English
VOLUNTARY ANNOUNCEMENT - JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-04-08	English
NEXT DAY DISCLOSURE RETURNS Transaction in Own Shares	2025-04-07	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2025 Regulatory Filings	2025-04-01	English
NEXT DAY DISCLOSURE RETURNS Transaction in Own Shares	2025-03-31	English
CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER Notice of Dividend Amount	2025-03-28	English
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2024 Earnings Release FY 2024	2025-03-28	English
VOLUNTARY ANNOUNCEMENT - SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-03-21	English
FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2024 Report Publication Announcement	2025-03-20	English
DATE OF BOARD MEETING Regulatory Filings	2025-03-18	English
VOLUNTARY ANNOUNCEMENT - JSKN003 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA Regulatory Filings	2025-03-18	English
VOLUNTARY ANNOUNCEMENT - SYH2051 (SELECTIVE ATM INHIBITOR) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-03-13	English
VOLUNTARY ANNOUNCEMENT - JMT108 (BI-FUNCTIONAL FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA Regulatory Filings	2025-03-05	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2025 Regulatory Filings	2025-03-03	English
VOLUNTARY ANNOUNCEMENT - SIROLIMUS FOR INJECTION (ALBUMIN-BOUND) WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA Regulatory Filings	2025-02-28	English
PROFIT WARNING Regulatory Filings	2025-02-25	English
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR SYS6005 WITH RADIANCE BIOPHARMA Regulatory Filings	2025-02-19	English
VOLUNTARY ANNOUNCEMENT - NEW INDICATION FOR ENYITAN (OMALIZUMAB FOR INJECTION) OBTAINS MARKETING APPROVAL Regulatory Filings	2025-02-10	English
VOLUNTARY ANNOUNCEMENT - SYH2059 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-02-10	English
VOLUNTARY ANNOUNCEMENT - SYS6017 (HERPES ZOSTER mRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL Regulatory Filings	2025-02-07	English
CHANGE OF SHARE REGISTRAR Regulatory Filings	2025-02-06	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2025 Regulatory Filings	2025-02-03	English
NEXT DAY DISCLOSURE RETURNS Transaction in Own Shares	2025-01-24	English
VOLUNTARY ANNOUNCEMENT - REGORAFENIB TABLETS OBTAINS DRUG REGISTRATION APPROVAL Regulatory Filings	2025-01-20	English
INDICATIVE RESULTS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2024 Earnings Release FY 2024	2025-01-17	English
VOLUNTARY ANNOUNCEMENT - SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. Regulatory Filings	2025-01-16	English
VOLUNTARY ANNOUNCEMENT - PRUSOGLIPTIN TABLETS OBTAINS MARKETING APPROVAL GRANTED BY NMPA Regulatory Filings	2025-01-13	English
VOLUNTARY ANNOUNCEMENT - SYS6041 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL Regulatory Filings	2025-01-10	English
NEXT DAY DISCLOSURE RETURNS Transaction in Own Shares	2025-01-09	English
NEXT DAY DISCLOSURE RETURNS Transaction in Own Shares	2025-01-08	English
VOLUNTARY ANNOUNCEMENT - SYS6045 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL Regulatory Filings	2025-01-07	English
VOLUNTARY ANNOUNCEMENT - SYH2059 TABLETS OBTAINS CLINICAL TRIAL APPROVAL Regulatory Filings	2025-01-07	English
NEXT DAY DISCLOSURE RETURNS Transaction in Own Shares	2025-01-07	English
NEXT DAY DISCLOSURE RETURNS Transaction in Own Shares	2025-01-06	English
NEXT DAY DISCLOSURE RETURNS Transaction in Own Shares	2025-01-03	English
NEXT DAY DISCLOSURE RETURNS Transaction in Own Shares	2025-01-02	English
VOLUNTARY ANNOUNCEMENT - SYS6010 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA Regulatory Filings	2025-01-02	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2024 Regulatory Filings	2025-01-02	English

Filings by year

2026 51 filings
2025 144 filings
2024 154 filings
2023 106 filings
2022 93 filings
2021 104 filings
2020 79 filings
2019 80 filings
2018 69 filings
2017 54 filings
2016 51 filings
2015 47 filings
2014 55 filings
2013 64 filings
2012 52 filings
2011 34 filings
2010 31 filings
2009 37 filings
2008 29 filings
2007 41 filings
2006 15 filings
2005 26 filings
2004 20 filings
2003 24 filings
2002 12 filings
2001 19 filings
2000 5 filings
1999 14 filings